drugset / Trial / NCT00827307

Zoladex Plus Tamoxifen in Breast Cancer

NCT00827307

Completed 100 enrolled Zhejiang Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare Zoladex plus tamoxifen with tamoxifen alone as adjuvant hormonal therapy in pre- or perimenopausal women with early-stage breast cancer in terms of breast density, estrogen levels, lipidemia, endometrial thickness and ultrasonographic abnormalities.

Timeline

Start
2008-06
Primary completion
2011-06
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous
Comparator Tamoxifen Small molecule 20 mg Oral

Indications